Nipah Virus Outbreak Strikes India; Weiboxin Biotech’s Diagnostic Reagents Fortify the First Line of Defense in Prevention and Control

Recently, an outbreak has occurred in West Bengal, India. Nipah virus outbreak , five confirmed cases have been reported, including several healthcare workers; nearly 100 people have been placed under home quarantine, and one patient is in critical condition, making the epidemic prevention and control situation extremely urgent. As The mortality rate is as high as 40%–75%. of Lethal Zoonotic Virus As there are no specific vaccines or antiviral drugs for Nipah virus, early surveillance and rapid screening are crucial for halting the spread of the outbreak.

Since its first discovery in Malaysia in 1998, the Nipah virus has been known for its Extremely high pathogenicity and transmission risk It has triggered global vigilance and been designated by the World Health Organization as a priority pathogen for research due to its pandemic potential. The recent outbreak in India once again underscores its dangerous characteristics: a prolonged incubation period ranging from 4 to 14 days, with a maximum of up to 45 days; early symptoms are nonspecific, including fever, headache, and vomiting, making them easy to overlook; in later stages, the condition can rapidly progress to somnolence, coma, and acute encephalitis, with severe cases leading to multi-organ failure and death—indeed, during the 2018 outbreak in Kerala, India, the case fatality rate reached as high as 91%.

Even more alarming is that the virus has a complex transmission route and can be transmitted through Contact with the bodily fluids of host animals such as fruit bats, or consumption of contaminated raw date palm juice or fruits. Achieve Animal-to-human transmission , can also be achieved through Close contact with respiratory secretions, saliva, and other bodily fluids of infected individuals Achieve Human-to-human transmission In particular, clustered transmission is prone to occur in households and healthcare settings, posing a significant challenge to epidemic prevention and control. Given the current lack of specific therapeutic agents, accurate and rapid early detection has become the first—and most critical—line of defense for identifying infected individuals and breaking the chain of transmission.

In the face of the severe Nipah virus outbreak, rapid screening and accurate diagnosis are critical measures for curbing its spread. With deep expertise in the diagnostics field and a strong foundation in R&D and technological innovation, Weiboxin Biotech has, in response to the sudden Nipah virus outbreak in India, launched Nipah Virus (NIPAH) Nucleic Acid Detection Kit (Fluorescent PCR Method) , thereby gaining valuable time for epidemic prevention and control.

This reagent boasts three core advantages that align with the practical needs of epidemic prevention and control: The first , with high sensitivity and specificity, it can effectively detect trace amounts of viral nucleic acid, thereby minimizing false-negative and false-positive results; Secondly , enabling rapid and efficient testing, significantly shortening the testing cycle, and helping institutions quickly screen suspected cases, isolate infected individuals, and curb person-to-person transmission; Thirdly It is easy to operate, compatible with standard laboratory testing equipment, and can be rapidly deployed in epidemic-affected areas to enhance grassroots monitoring capabilities.

From screening suspected cases to monitoring close contacts, from assessing the epidemic situation to adjusting prevention and control strategies, Weiboxin Biotechnology’s Nipah virus detection reagents provide end-to-end support, comprehensively bolstering customs and disease control agencies in their epidemic surveillance and prevention and control efforts. Provide reliable diagnostic tools for India and the global response to the Nipah virus outbreak, thereby supporting the establishment of a closed-loop prevention and control system characterized by “early detection, early isolation, and early containment.”

Nucleic acid extraction reagent (magnetic bead-based), which is compatible with the vast majority of both imported and domestically produced automated extraction instruments on the market.

Weiboxin Bio’s nucleic acid extraction reagents are pre-encapsulated, requiring only a single manual step. A variety of extraction kits are available to meet the needs of different sample types and pathogens. These reagents are also compatible with Weiboxin Bio’s fully automated high-throughput nucleic acid extractors, including 32- and 96-well models.

For animal disease testing reagents, please choose the Weiboxin brand.

Be aware of Weiboxin Bio All products of!

Official consultation phone numbers: 020-82298089 / 135 3988 6748, Ms. Dai

Overseas Service Hotline (Mobile/WhatsApp/WeChat): +86 18902342201

Email: sara@viuick.com

Guangzhou Weiboxin Biotechnology Co., Ltd. is a provincial-level “Little Giant” high-tech enterprise specializing in the forward R&D, manufacturing, sales, and technical services of diagnostic reagents for infectious diseases. The company is also recognized as a “Contract-Honoring and Credit-Keeping Enterprise” by Guangdong Province and a “Provincial Intellectual Property Demonstration Unit.” It serves as an industry–university–research collaboration base for Guangdong Food and Drug Vocational College and holds a standing directorship on the Veterinary Diagnostic and Biological Products Committee of the Guangdong Society of Animal Husbandry and Veterinary Medicine. Furthermore, it has been designated as an innovative, high-potential enterprise by multiple research institutions, including the Entrepreneurship College of Jinan University in Guangdong Province, and has been awarded the titles of “Specialized, Refined, Distinctive, and Innovative” enterprise at both municipal and provincial levels. The company has received the “Most Investment-Valuable Enterprise” award and the annual title of “ASF and Swine Disease Testing Service Provider,” and has obtained the approval number for veterinary drug products from the Ministry of Agriculture and Rural Affairs. : Veterinary Drug Registration No. 191438923 (Fluorescent PCR Detection Kit for African Swine Fever Virus) 、 Veterinary Drug Registration No. 191438213 (Porcine Reproductive and Respiratory Syndrome Virus ELISA Antibody Detection Kit) 、 Veterinary Drug Registration No. 191438875 (Classical Swine Fever Virus Blocking ELISA Antibody Detection Kit) and Veterinary Drug Registration No. 191438851 (Porcine Circovirus Type 2 ELISA Antibody Detection Kit) The company has been recognized with the Excellence Award in the Growth Category of the Biopharmaceutical Industry at the 11th China Innovation and Entrepreneurship Competition, as well as the Provincial Second Prize in the Growth Category of the Nanotechnology Industry Technology Competition under the Science and Technology Innovation and Entrepreneurship Contest. Furthermore, it secured the National Third Prize in the Growth Category at the National Finals of the Nanotechnology Industry Technology Innovation Special Competition within the China Innovation and Entrepreneurship Competition. The company has also consecutively received the A-Level Tax Credit Certificate, the Four-Star Trademark and Brand Certification, and the Two-Integration Management System Assessment Certificate each year. In addition, it holds ISO 9001 International Quality Management System Certification, ISO 14001 International Environmental Management System Certification, and GMP Certification from the Ministry of Agriculture. Since its establishment, the company has been granted a total of 24 patents, including 5 invention patents, 15 utility model patents, and 4 design patents, along with more than ten trademarks.

The company boasts robust technical capabilities and a world-class team of professionals, including dozens of masters, doctors, and returnees who studied abroad, as well as numerous senior-title technical experts. Currently, the company’s primary focus is on the R&D of molecular diagnostic reagents. Its core R&D team has developed more than 600 products spanning molecular diagnostics and immunoassays, including public-health–oriented fluorescent PCR test kits, animal disease–control–oriented fluorescent PCR test kits, clinical and research–grade fluorescent quantitative PCR kits, and transgenic–identification test kits (ZL2006). The company has established a nationwide distribution network covering over ten major cities, such as Beijing, Shanghai, Hangzhou, Nanjing, Wuhan, Xi’an, Yunnan, Chongqing, Chengdu, Guizhou, Lanzhou, Zhengzhou, Qingdao, Inner Mongolia, and Xinjiang. Moreover, its products are now exported to numerous overseas markets, including the United Arab Emirates, Oman, Egypt, Pakistan, Paraguay, Poland, Colombia, Kazakhstan, Mongolia, Bangladesh, Myanmar, Mexico, Nigeria, Saudi Arabia, Spain, Armenia, India, Indonesia, Vietnam, Cambodia, and others, providing high-quality products and services to customers worldwide.

Looking ahead, Weiboxin will remain steadfast in its commitment to continuously enhance product quality and service standards. Leveraging a rapid and efficient research platform and abundant biomedical resources, we will conduct extensive and in-depth R&D and scientific research in the biomedical field, thereby contributing to human health and advancing life sciences. Quality is our lifeline; innovation is our soul. Upholding this guiding principle, we will relentlessly strive to become the premier supplier of rapid diagnostic reagents and instruments.